• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠血浆中恩杂鲁胺测定的超高效液相色谱-串联质谱法的建立与验证及其药代动力学应用

Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application.

作者信息

Li Shuang-Long, Zhu Yong-Liang, Zhang Yi, Liu Shu-Han, Wang Xiang-Die, Qiu Xiang-Jun

机构信息

Medical College of Henan University of Science and Technology, Luoyang 471023, China.

出版信息

Int J Anal Chem. 2020 Mar 31;2020:5084127. doi: 10.1155/2020/5084127. eCollection 2020.

DOI:10.1155/2020/5084127
PMID:32292480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7150726/
Abstract

In our research, a straightforward UPLC-MS/MS method, with diazepam as the internal standard (IS), was proposed and acknowledged to determine the concentrations of enasidenib in rat plasma. When preparing the sample, we used acetonitrile for protein precipitation. The gradient elution method was used, and the mobile phase was acetonitrile and 0.1% formic acid. Diazepam was used as the IS. We used the Acquity UPLC BEH C18 column to separate enasidenib and IS. Under the positive ion electrospray ionization (ESI) source conditions, the mass transfer pairs of enasidenib were monitored by multiple reaction monitoring (MRM) to be 474.2 ⟶ 456.1 and 474.2 ⟶ 267.0, and the IS mass transfer pairs were 285.0 ⟶ 154.0. Enasidenib had good linearity (  = 0.9985) in the concentration range of 1.0-1000 ng/mL. Besides, the values of intraday and interday precision were 2.25-8.40% and 3.94-5.46%, respectively, and the range of the accuracy values varied from -1.44 to 2.34%. Matrix effect, extraction recovery, and stability were compliant with FDA approval guidelines in terms of bioanalytical method validation. We had established a new method that had been applied to the pharmacokinetic study of enasidenib in rats.

摘要

在我们的研究中,提出了一种以地西泮为内标(IS)的简单超高效液相色谱-串联质谱(UPLC-MS/MS)方法,并被认可用于测定大鼠血浆中恩杂鲁胺的浓度。在制备样品时,我们使用乙腈进行蛋白沉淀。采用梯度洗脱方法,流动相为乙腈和0.1%甲酸。地西泮用作内标。我们使用 Acquity UPLC BEH C18 柱分离恩杂鲁胺和内标。在正离子电喷雾电离(ESI)源条件下,通过多反应监测(MRM)监测恩杂鲁胺的质荷比为474.2⟶456.1和474.2⟶267.0,内标的质荷比为285.0⟶154.0。恩杂鲁胺在1.0 - 1000 ng/mL浓度范围内具有良好的线性(r = 0.9985)。此外,日内和日间精密度值分别为2.25 - 8.40%和3.94 - 5.46%,准确度值范围为 -1.44至2.34%。在生物分析方法验证方面,基质效应、提取回收率和稳定性均符合美国食品药品监督管理局(FDA)的批准指南。我们建立了一种新方法,并已将其应用于恩杂鲁胺在大鼠体内的药代动力学研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/bfdf387855e5/IJAC2020-5084127.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/f01263f6295d/IJAC2020-5084127.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/0725a7bdf140/IJAC2020-5084127.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/7744bda28577/IJAC2020-5084127.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/bfdf387855e5/IJAC2020-5084127.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/f01263f6295d/IJAC2020-5084127.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/0725a7bdf140/IJAC2020-5084127.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/7744bda28577/IJAC2020-5084127.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f512/7150726/bfdf387855e5/IJAC2020-5084127.004.jpg

相似文献

1
Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application.大鼠血浆中恩杂鲁胺测定的超高效液相色谱-串联质谱法的建立与验证及其药代动力学应用
Int J Anal Chem. 2020 Mar 31;2020:5084127. doi: 10.1155/2020/5084127. eCollection 2020.
2
UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics.基于药代动力学的 UPLC-MS/MS 法研究消癌平注射液对恩西地平在大鼠体内的相互作用
Biomed Res Int. 2021 Feb 23;2021:6636266. doi: 10.1155/2021/6636266. eCollection 2021.
3
Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC-MS/MS.采用 UPLC-MS/MS 法测定大鼠血浆中的依尼西尼布及其药代动力学研究。
J Pharm Biomed Anal. 2018 Aug 5;157:165-170. doi: 10.1016/j.jpba.2018.04.039. Epub 2018 Apr 27.
4
UPLC-MS/MS assay of 21-aminosteroid (lazaroid U74389G) for application in pharmacokinetic study.用于药代动力学研究的21-氨基类固醇(拉扎罗类化合物U74389G)的超高效液相色谱-串联质谱分析。
J Pharm Biomed Anal. 2016 Apr 15;122:90-7. doi: 10.1016/j.jpba.2016.01.033. Epub 2016 Jan 16.
5
UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma.UPLC-MS/MS 法同时测定大鼠血浆中伊马替尼、伏立康唑及其代谢物浓度。
J Pharm Biomed Anal. 2019 Mar 20;166:6-12. doi: 10.1016/j.jpba.2018.12.036. Epub 2018 Dec 21.
6
UPLC-MS/MS determination and gender-related pharmacokinetic study of five active ingredients in rat plasma after oral administration of Eucommia cortex extract.超高效液相色谱-串联质谱法测定杜仲皮提取物口服给药后大鼠血浆中5种活性成分及其性别相关的药代动力学研究
J Ethnopharmacol. 2015 Jul 1;169:145-55. doi: 10.1016/j.jep.2015.04.007. Epub 2015 Apr 22.
7
Determination of songorine in rat plasma by UPLC-MS/MS: Assay development and application to pharmacokinetic study.超高效液相色谱-串联质谱法测定大鼠血浆中的槐定碱:方法学建立及其在药代动力学研究中的应用
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:234-8. doi: 10.1016/j.jchromb.2015.08.037. Epub 2015 Aug 28.
8
Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study.超高效液相色谱-串联质谱法同时测定大鼠血浆中波生坦、格列美脲、HYBOS和M1及其在药代动力学研究中的应用
J Chromatogr Sci. 2016 Aug;54(7):1159-65. doi: 10.1093/chromsci/bmw003. Epub 2016 May 30.
9
Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study.验证的超高效液相色谱-串联质谱法用于大鼠血浆中呋喹替尼的定量及其在药代动力学研究中的应用。
Drug Des Devel Ther. 2019 Aug 15;13:2865-2871. doi: 10.2147/DDDT.S199362. eCollection 2019.
10
UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma.UPLC-MS/MS 法测定大鼠血浆中厄格列净和西他列汀的浓度。
Anal Biochem. 2019 Feb 15;567:112-116. doi: 10.1016/j.ab.2018.12.016. Epub 2018 Dec 20.

引用本文的文献

1
UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics.基于药代动力学的 UPLC-MS/MS 法研究消癌平注射液对恩西地平在大鼠体内的相互作用
Biomed Res Int. 2021 Feb 23;2021:6636266. doi: 10.1155/2021/6636266. eCollection 2021.

本文引用的文献

1
Quantitative analysis of enasidenib in dried blood spots of mouse blood using an increased-sensitivity LC-MS/MS method: Application to a pharmacokinetic study.使用提高灵敏度的液相色谱-串联质谱法对小鼠血液干血斑中的恩杂鲁胺进行定量分析:在药代动力学研究中的应用。
Biomed Chromatogr. 2019 Jun;33(6):e4491. doi: 10.1002/bmc.4491. Epub 2019 Feb 7.
2
Progress in the problem of relapsed or refractory acute myeloid leukemia.复发或难治性急性髓系白血病问题的研究进展。
Curr Opin Hematol. 2019 Mar;26(2):88-95. doi: 10.1097/MOH.0000000000000490.
3
Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects.
在日本和白种人群体中单次口服依尼西尼布的药代动力学和安全性。
Pharmacol Res Perspect. 2018 Oct 23;6(6):e00436. doi: 10.1002/prp2.436. eCollection 2018 Dec.
4
Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.恩杂鲁胺:首个用于治疗难治性和复发性急性髓系白血病的突变型异柠檬酸脱氢酶2抑制剂。
Anticancer Agents Med Chem. 2018;18(14):1936-1951. doi: 10.2174/1871520618666181025091128.
5
The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.恩杂鲁胺在治疗突变型异柠檬酸脱氢酶2急性髓系白血病中的作用。
Ther Adv Hematol. 2018 Jul;9(7):163-173. doi: 10.1177/2040620718777467. Epub 2018 Jun 1.
6
Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia.骨髓微环境在急性髓系白血病的造血、白血病发生及化疗耐药中的作用
Hematology. 2018 Dec;23(10):729-739. doi: 10.1080/10245332.2018.1486064. Epub 2018 Jun 14.
7
Enasidenib for relapsed/refractory acute myeloid leukemia with IDH2 mutations: optimizing the patient experience.恩杂鲁胺用于治疗伴有异柠檬酸脱氢酶2(IDH2)突变的复发/难治性急性髓系白血病:优化患者体验
Clin Adv Hematol Oncol. 2018 May;16(5):322-325.
8
Determination and pharmacokinetic study of Enasidenib in rat plasma by UPLC-MS/MS.采用 UPLC-MS/MS 法测定大鼠血浆中的依尼西尼布及其药代动力学研究。
J Pharm Biomed Anal. 2018 Aug 5;157:165-170. doi: 10.1016/j.jpba.2018.04.039. Epub 2018 Apr 27.
9
Enasidenib for the treatment of acute myeloid leukemia.依尼西单抗治疗急性髓系白血病。
Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760. doi: 10.1080/17512433.2018.1477585. Epub 2018 Jul 24.
10
Absorption, distribution, metabolism and excretion of an isocitrate dehydrogenase-2 inhibitor enasidenib in rats and humans.异柠檬酸脱氢酶-2抑制剂恩杂鲁胺在大鼠和人类体内的吸收、分布、代谢及排泄情况。
Xenobiotica. 2019 Feb;49(2):200-210. doi: 10.1080/00498254.2018.1425511. Epub 2018 Jan 22.